C4 Therapeutics, Inc. (CCCC) stock chart
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.89−0.11 (-3.67%)
Close on Nov 11, 2026Market cap $355.54MP/E –Yield –
Daily, weekly, monthly, quarterly and yearly candles from end-of-day prices, adjusted for splits. Marks along the bottom: E for earnings, D for ex-dividend dates, S for stock splits. Drawings are saved in this browser for each symbol; indicators and chart settings carry across symbols.
See a number that looks wrong?